EN DE
Watch Alibaba Health Information Technology Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Alibaba Health Information Technology Ltd (0241) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Alibaba Health Information Technology Ltd stock HK$2.39, price HK$3.05, that is 21.5% below the price, quality 64 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN BMG0171K1018

AH Alibaba Health Information Technology Ltd logo Thin data Nov 6, 2026

Alibaba Health Information Technology Ltd

0241 · HK
Expensive, in a downtrend

Our calculation puts a fair price 22% below what the stock costs today.

Quality 64/100
Healthy Growth (revenue 5y +17.2 %/yr in HKD)
Low debt
Generates free cash flow
2.0% dividend yield · Sustainable
Thin margins · 5.7% net margin (TTM)
Mixed vs. peers (7/14)
Moderate moat 49/100
Neutral coverage
Fair value HK$2.39 · Overvalued
Thin data

Risks from the AI analysis

🚩Price drop: Regulatory overhang from acquisition ruling🚩Regulatory ruling on parent's 2014 acquisition breach🚩Stricter prescription rules raise compliance costs🚩Rivals like JD Health and Meituan intensify price pressure
Watch Alibaba Health Information Technology Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$17.76 HK$2.56 Fair Value HK$2.39 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range HK$2.56 – HK$17.76 · fair‑value band HK$1.47 – HK$3.28 · the HK$3.05 price screens above the HK$2.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Alibaba Health Information Technology in your weekly email

Every Wednesday you see whether Alibaba Health Information Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong.

Show moreShow less

The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products.

It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines.

The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark.

In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions.

The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.

Stock analysis

Alibaba Health Information Technology Ltd (0241) currently trades at HK$3.05, while our model-based Fair Value estimate is HK$2.39, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$6.52 per share, and 8 of the 26 models we run sit above the HK$3.05 price.

Bear case: the Dividend Discount group reads lowest at HK$0.5800, and 18 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$1.47 (bear) to HK$3.28 (bull), the price of HK$3.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Alibaba Health Information Technology Ltd reported revenue of 34.3B CNY in FY2026 versus 20.6B CNY in FY2022, a compound +13.6%/yr. Reported net income was 1.9B CNY in FY2026.

Key figures

Market cap HK$49.3B (≈ $6.3B) Mid · P/E ratio 21.9 · P/S ratio 0.82 · EPS (TTM) HK$0.0800 · Dividend yield 2.0% · Net margin 5.7% · Return on equity 11.3% · Return on assets (EBIT) 2.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 60% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 24% fair-value upside, at −22%, 0241 screens richer than that median.

Fair Value models

Bear HK$1.47 Fair Value HK$2.39 Bull HK$3.28
Price HK$3.05 · Downside -21.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (HK$0.0122 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$1.54 HK$2.03 HK$3.45 77
Growth DCF HK$1.47 HK$2.18 HK$3.28 75
EPV HK$1.09 HK$1.18 HK$1.25 74
All 26 models by family
DCF Models
FCF DCF HK$1.54 HK$2.03 HK$3.45 77
Owner Earnings HK$1.27 HK$2.13 HK$3.67 72
5Y Revenue Exit HK$1.54 HK$2.37 HK$4.09 68
5Y EBITDA Exit HK$1.63 HK$2.54 HK$4.32 71
5Y P/E Exit HK$2.34 HK$4.90 HK$8.42 66
10Y Revenue Exit HK$1.51 HK$2.77 HK$3.57 65
10Y EBITDA Exit HK$1.60 HK$2.93 HK$5.22 63
10Y P/E Exit HK$2.06 HK$4.29 HK$8.02 58
Earnings-Based
Graham-Dodd HK$0.9600 HK$6.66 HK$9.35 61
Lynch FV HK$3.44 HK$4.92 HK$6.39 59
PEG = 1.0 HK$3.44 HK$4.92 HK$6.39 55
EPV HK$1.09 HK$1.18 HK$1.25 74
Dividend Discount
Gordon GGM HK$0.3400 HK$0.6000 HK$0.7900 66
DDM Multi-Stage HK$0.3400 HK$0.5600 HK$0.6400 65
Multiples
P/E Multiple HK$2.32 HK$3.09 HK$3.86 63
P/S Multiple HK$1.79 HK$2.39 HK$2.98 58
P/B Multiple HK$4.10 HK$5.46 HK$6.83 55
EV/EBIT HK$1.87 HK$2.36 HK$2.84 66
EV/EBITDA HK$1.65 HK$2.07 HK$2.48 67
EV/Revenue HK$1.45 HK$1.90 HK$2.34 54
Asset-Based
NCAV (Graham) HK$0.4900 HK$0.7400 HK$0.9200 55
Growth DCF
Growth DCF HK$1.47 HK$2.18 HK$3.28 75
Rev-Margin DCF HK$1.66 HK$2.65 HK$4.71 68
Economic Profit
Residual Income HK$1.07 HK$1.17 HK$1.37 74
ROIC Compounder HK$1.09 HK$1.18 HK$1.25 70
Growth Earnings
Growth-Adj P/E HK$4.57 HK$6.52 HK$8.48 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 64/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 60
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 41
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 28
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 47
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Start year 2021 (pandemic). Over 10 years: +89.8% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.4%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+38.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+36.9%
Dividend (yield on the price)2.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 5%
2026 sits 91% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +17.4% a year for the price and +6.9% for the forecasts.
Forecast 2027 (sales)+9.1%
Forecast 2028 (sales)+10.1%
Projected 2029 (sales)+9.1%
Projected 2030 (sales)+8.1%
Projected 2031 (sales)+7.1%

0241 screens overvalued: fair value 22% below the price. Compare with JD Health International Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (78 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Note from the team Nov 8, 2026
AI conclusion: Moderate moat supported by solid cash conversion and zero debt offers stability, yet low innovation and typical retailer pricing pressure constrain the business.
Main risk: New guidelines requiring licensed pharmacists instead of AI for prescription reviews could increase staffing costs and slow order processing for Alibaba Health's high-volume online pharmacy business.
Bull case: Alibaba Health could leverage its Alibaba ecosystem integration and selective AI tools where permitted to streamline operations and maintain an edge over rivals despite tighter rules.
Bear case: If regulatory costs rise sharply and rivals gain ground in instant delivery, Alibaba Health could see slower growth and squeezed margins in its core pharmaceutical retail operations.
Alibaba Health faces a recent regulatory ruling that its parent breached takeover rules in the 2014 acquisition through a special deal not extended to all shareholders. Our models currently see the stock as overvalued. Will an appeal clear the overhang or will ties to the group keep drawing scrutiny that limits the pharmaceutical retail platform?
Join the discussion →

Compare Alibaba Health Information Technology Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside −21.5% · Bottom 25%
Profitability
Return on equity (12 months) 11.3% · Above median
Return on assets 8.4% · Top 25%
Net margin (12 months) 5.7% · Top 25%
Operating margin (12 months) 4.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) 7.6% · Above median
Dividend yield (12 months) 2.0% · Below median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (12 months) 21.9× · Pricier than median
P/B 2.77× · Pricier than median
P/S (12 months) 1.44× · Priciest 25%
Price / free cash flow (fiscal year) 40.2× · Priciest 25%
EV/EBITDA 23.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 66
FUTURE (revenue growth)38 · sector 21
PAST (return on equity)45 · sector 32
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)39 · sector 60

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
JD Health International Inc 6618 HK$43.00 HK$75.61 +76% vs 0241
Luyan Pharma Co 002788 ¥9.36 ¥15.91 +70% vs 0241
Yifeng Pharmacy Chain Co 603939 ¥25.32 ¥40.59 +60% vs 0241
Yixintang Pharmaceutical Group 002727 ¥12.98 ¥18.92 +46% vs 0241
DaShenLin Pharmaceutical Group 603233 ¥20.54 ¥25.52 +24% vs 0241
MedPlus Health Services Limited MEDPLUS ₹596.00 ₹707.67 +19% vs 0241
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.38 ¥16.43 +14% vs 0241
Anhui Huaren Health Pharmaceutical Co 301408 ¥13.79 ¥15.40 +12% vs 0241
ShuYu Civilian Pharmacy Corp 301017 ¥14.06 ¥5.91 −58% vs 0241
Apotea AB APOTEA kr 104.30 kr 39.50 −62% vs 0241

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alibaba Health Information Technology Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Alibaba Health Information Technology Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0241

Frequently asked questions

Is Alibaba Health Information Technology Ltd (0241) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of HK$2.39 versus a price of HK$3.05, about 22% lower (overvalued).
What is the fair value of 0241?
Our model-based fair value for Alibaba Health Information Technology Ltd is HK$2.39 (as of Nov 6, 2026), built from audited fundamentals. The current price: HK$3.05.
What is the quality score of 0241?
Alibaba Health Information Technology Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alibaba Health Information Technology Ltd (0241)?
Our model-based price target is the fair value of HK$2.39 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario HK$1.47, optimistic scenario HK$3.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Alibaba Health Information Technology Ltd stock forecast for 2026?
Our models put fair value at HK$2.39, about 22% lower versus a price of HK$3.05 (overvalued). Cautious scenario HK$1.47, optimistic scenario HK$3.28. The calculation is refreshed regularly with new filings.
What is the revenue of Alibaba Health Information Technology Ltd (0241)?
Alibaba Health Information Technology Ltd reported trailing-twelve-month revenue of about HK$34.3B (latest available figure, as of Nov 6, 2026).
Does Alibaba Health Information Technology Ltd pay a dividend?
Alibaba Health Information Technology Ltd currently shows a dividend yield of 1.97% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Alibaba Health Information Technology Ltd (0241) and when is the ex-dividend date?
Alibaba Health Information Technology Ltd pays a dividend of HK$0.06 per share a year, a dividend yield of 2.0%. The last ex-dividend date was Aug 12, 2026. The payout ratio is 75.0% of earnings. Free cash flow covers the dividend 1.26 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Alibaba Health Information Technology Ltd (0241)?
For today's price to be fair in a discounted-cash-flow model, Alibaba Health Information Technology Ltd would have to grow free cash flow by +19.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 0241 use?
Our models discount Alibaba Health Information Technology Ltd at 11.8 %: a base by market capitalisation (mid), damped by beta 1.58, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alibaba Health Information Technology Ltd that is +19.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Alibaba Health Information Technology Ltd (0241) delivered so far?
Over the past 5 years revenue at Alibaba Health Information Technology Ltd grew +17.2 % a year. The price currently implies free-cash-flow growth of +19.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alibaba Health Information Technology Ltd (0241) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Alibaba Health Information Technology Ltd (+19.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alibaba Health Information Technology Ltd (0241)?
The free-cash-flow yield on the price is 2.93 %: that much free cash flow Alibaba Health Information Technology Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alibaba Health Information Technology Ltd (0241)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alibaba Health Information Technology Ltd it is HK$2.39 per share (as of Nov 6, 2026), against a price of HK$3.05. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Alibaba Health Information Technology Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 0241 trades above its calculated fair value: price HK$3.05, fair value HK$2.39, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0241?
No. The price is what the market pays today (HK$3.05); the fair value is what the company's own numbers justify (HK$2.39). For Alibaba Health Information Technology Ltd the two are HK$0.6550 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alibaba Health Information Technology Ltd worth?
The market values Alibaba Health Information Technology Ltd at about HK$49.3B (market capitalisation, as of Nov 6, 2026). Per share that is HK$3.05; our models calculate a fair value of HK$2.39 per share.
What do the bullish and bearish scenarios say about 0241?
Our models span a range for Alibaba Health Information Technology Ltd: cautious scenario HK$1.47, base HK$2.39, optimistic HK$3.28 per share (as of Nov 6, 2026, price HK$3.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0241?
Alibaba Health Information Technology Ltd trades at a price-to-earnings ratio of 21.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$2.39 is built from several models across several years. Other multiples: PEG 0.7, P/B 2.8, P/S 1.4, EV/EBITDA 23.4.
What is the PEG ratio of 0241?
The PEG ratio of Alibaba Health Information Technology Ltd is 0.69 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Alibaba Health Information Technology Ltd (0241)?
Balance-sheet figures for Alibaba Health Information Technology Ltd (as of Nov 6, 2026): return on equity 11.3%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 0241 from its 52-week high?
Alibaba Health Information Technology Ltd trades at HK$3.05, about 60% below its 52-week high of HK$7.63 and 11% above the low of HK$2.76 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.39 is for.
Which stocks are comparable to Alibaba Health Information Technology Ltd?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alibaba Health Information Technology Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price HK$3.05, calculated fair value HK$2.39 (−22%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0241 calculated?
We run Alibaba Health Information Technology Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$2.39 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Alibaba Health Information Technology Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alibaba Health Information Technology Ltd (0241)?
The closing price on Nov 9, 2026 was HK$3.05. Our model-based fair value is HK$2.39, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alibaba Health Information Technology Ltd right now?
Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$1.47 to HK$3.28) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Alibaba Health Information Technology Ltd

How large is the market capitalisation of Alibaba Health Information Technology Ltd (0241)?
The market capitalisation of Alibaba Health Information Technology Ltd is HK$49.3B (≈ $6.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alibaba Health Information Technology Ltd (0241)?
The price-to-sales ratio of Alibaba Health Information Technology Ltd is 0.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alibaba Health Information Technology Ltd (0241)?
Earnings per share at Alibaba Health Information Technology Ltd are HK$0.0800 (price ÷ EPS = P/E 21.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Alibaba Health Information Technology Ltd (0241)?
The dividend yield of Alibaba Health Information Technology Ltd is 2.0% (payout 75.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Alibaba Health Information Technology Ltd (0241)?
The net margin of Alibaba Health Information Technology Ltd is 5.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alibaba Health Information Technology Ltd (0241)?
The return on equity (ROE) of Alibaba Health Information Technology Ltd is 11.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alibaba Health Information Technology Ltd (0241)?
On an EBIT basis the return on assets of Alibaba Health Information Technology Ltd is 2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alibaba Health Information Technology Ltd (0241)?
The operating margin of Alibaba Health Information Technology Ltd is 4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alibaba Health Information Technology Ltd (0241)?
Revenue at Alibaba Health Information Technology Ltd is growing +7.6% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alibaba Health Information Technology Ltd (0241)?
Earnings per share at Alibaba Health Information Technology Ltd are growing +0.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Alibaba Health Information Technology Ltd (0241) hold?
Alibaba Health Information Technology Ltd holds more cash than debt, HK$5.7B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Alibaba Health Information Technology Ltd in the live analysis

One click puts Alibaba Health Information Technology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.